Psilocybin-assisted therapy and HIV-related shame.

Sci Rep

Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, Sandler Neurosciences Bldg., Rm 510, 675 Nelson Rising Lane, San Francisco, CA, 94143, USA.

Published: August 2024

As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of increased rates of substance use and difficulties adhering to antiretroviral treatment among people with HIV. These downstream manifestations have ultimately impeded progress toward national goals to End the HIV Epidemic, in part due to limited success of conventional psychotherapies in addressing HIV-related shame. In a pilot clinical trial (N = 12), receipt of psilocybin-assisted group therapy was associated with a large pre-post decrease in HIV-related shame as measured by the HIV and Abuse Related Shame Inventory, with a median (IQR) change of - 5.5 (- 6.5, - 3.5) points from baseline to 3-months follow-up (Z = - 2.6, p = 0.009, r = - 0.75). A paradoxical exacerbation of sexual abuse-related shame experienced by two participants following receipt of psilocybin raises critical questions regarding the use of psilocybin therapy among patients with trauma. These preliminary findings carry potential significance for the future of HIV care.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11297300PMC
http://dx.doi.org/10.1038/s41598-024-68908-4DOI Listing

Publication Analysis

Top Keywords

hiv-related shame
16
shame
6
psilocybin-assisted therapy
4
hiv-related
4
therapy hiv-related
4
shame proposed
4
proposed mediator
4
mediator stigma-related
4
stigma-related stressors
4
stressors negative
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!